Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors
暂无分享,去创建一个
E. Moding | C. Kunder | P. Ghanouni | K. Ganjoo | R. Avedian | L. Million
[1] A. Napoli,et al. Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study , 2017, European Radiology.
[2] G. Gold,et al. Is MR-guided High-intensity Focused Ultrasound a Feasible Treatment Modality for Desmoid Tumors? , 2016, Clinical orthopaedics and related research.
[3] S. Gwyther,et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] T. Yen,et al. Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Bristow,et al. Imatinib radiosensitizes bladder cancer by targeting homologous recombination. , 2013, Cancer research.
[6] P. Terrier,et al. The treatment of desmoid tumors: a stepwise clinical approach. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Blay,et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] Dafydd G. Thomas,et al. Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial , 2010, Clinical Cancer Research.
[9] W. Jonat,et al. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells , 2010, BMC Cancer.
[10] Susan C. Weber,et al. STRIDE - An Integrated Standards-Based Translational Research Informatics Platform , 2009, AMIA.
[11] L. Mariani,et al. Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment , 2009, Annals of Surgical Oncology.
[12] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[13] M. Ballo,et al. Long-term outcomes for desmoid tumors treated with radiation therapy. , 2008, International journal of radiation oncology, biology, physics.
[14] R. Yerushalmi,et al. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. , 2007, Experimental oncology.
[15] J. Debus,et al. Human Glioblastoma and Carcinoma Xenograft Tumors Treated by Combined Radiation and Imatinib (Gleevec®) , 2006, Strahlentherapie und Onkologie.
[16] J. Fletcher,et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] B. Dörken,et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. , 2005, Blood cells, molecules & diseases.
[18] V. Sondak,et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate , 2002, Cancer.
[19] Charles R. Thomas,et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors , 2000, Cancer.
[20] R. Cofield,et al. Osteonecrosis of the humeral head: relationship of disease stage, extent, and cause to natural history. , 1999, Journal of shoulder and elbow surgery.
[21] W. Gerald,et al. Desmoid fibromatosis is a clonal process. , 1996, Human pathology.